Literature DB >> 7359154

Monitoring fibrinolytic activity in the cerebrospinal fluid after aneurysmal subarachnoid haemorrhage: a guide to the risk of rebleeding?

R S Maurice-Williams, Y B Gordon, A Sykes.   

Abstract

Serial assay of fibrin degradation products (FDPs) was used to monitor fibrinolytic activity in blood and cerebrospinal fluid (CSF) after subarachnoid haemorrhage (SAH) in 64 patients, 43 of whom had aneurysms. CSF levels fell rapidly from high initial values over a few days, thereafter more slowly to reach normal levels after one to six weeks. Probably only the later slow decline is a measure of fibrinolysis, which is obscured in the first few days by the cross antigenicity with FDP's of fibrinogen released by the bleed. After this phase of fibrinogen clearance, early attainment of normal FDP levels appears to be associated with a lower risk of rebleeding in cases of aneurysm. This phenomenon could be useful in deciding whether marginal cases should be treated surgically or conservatively.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7359154      PMCID: PMC490495          DOI: 10.1136/jnnp.43.2.175

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  20 in total

1.  Specific and sensitive determination of fibrinogen-degradation products by radioimmunoassay.

Authors:  Y B Gordon; M J Martin; A T McNeile; T Chard
Journal:  Lancet       Date:  1973-11-24       Impact factor: 79.321

2.  Monitoring antifibrinolytic therapy in subarachnoid hemorrhage.

Authors:  R R Smith; J J Upchurch
Journal:  J Neurosurg       Date:  1973-03       Impact factor: 5.115

3.  Earlier operation and antifibrinolytic therapy in the management of aneurysmal subarachnoid haemorrhage. Review of recent experience in Tasmania.

Authors:  G Corkill
Journal:  Med J Aust       Date:  1974-03-30       Impact factor: 7.738

4.  Fibrin-fibrinogen degradation products in cerebrospinal fluid of patients admitted to a psychiatric unit.

Authors:  R Hunter; T Thomson; C M Reynolds; P M Pitcher
Journal:  J Neurol Neurosurg Psychiatry       Date:  1974-03       Impact factor: 10.154

5.  Preoperative management of patients with ruptured intracranial aneurysms.

Authors:  J Ransohoff; A Goodgold; M V Benjamin
Journal:  J Neurosurg       Date:  1972-05       Impact factor: 5.115

6.  Treatment of subarachnoid hemorrhage: the ability of epsilon aminocaproic acid to cross the blood brain barrier and reduce the spinal fluid fibrinolytic activity.

Authors:  B J Levy; D Silver
Journal:  Surg Forum       Date:  1968

7.  Experimental and clinical studies on AMCA, the antifibrinolytically active isomer of p-aminomethyl cyclohexane carboxylic acid.

Authors:  L Andersson; I M Nilsson; J E Niléhn; U Hedner; B Granstrand; B Melander
Journal:  Scand J Haematol       Date:  1965

8.  Antifibrinolytic therapy in ruptured intracranial aneurysm through repeated monitoring of fibrinolytic activity of blood.

Authors:  H Watanabe; M Ito; H Chigasaki; S Ishii
Journal:  Neurol Med Chir (Tokyo)       Date:  1976       Impact factor: 1.742

9.  Use of epsilon aminocaproic acid (EACA) in the preoperative management of ruptured intracranial aneurysms.

Authors:  R P Sengupta; S C So; F J Villarejo-Ortega
Journal:  J Neurosurg       Date:  1976-04       Impact factor: 5.115

10.  Intracranial aneurysms and subarachnoid hemorrhage. A cooperative study. Antifibrinolytic therapy in recent onset subarachnoid hemorrhage.

Authors:  D W Nibbelink; J C Torner; W G Henderson
Journal:  Stroke       Date:  1975 Nov-Dec       Impact factor: 7.914

View more
  10 in total

Review 1.  Antifibrinolytic agents in subarachnoid haemorrhage.

Authors:  K W Lindsay
Journal:  J Neurol       Date:  1987-01       Impact factor: 4.849

2.  Ruptured intracranial aneurysms: has the incidence of early rebleeding been over-estimated?

Authors:  R S Maurice-Williams
Journal:  J Neurol Neurosurg Psychiatry       Date:  1982-09       Impact factor: 10.154

3.  Fibrinolytic activity after subarachnoid haemorrhage and the effect of tranexamic acid.

Authors:  S A Tsementzis; W P Honan; S Nightingale; E R Hitchcock; C H Meyer
Journal:  Acta Neurochir (Wien)       Date:  1990       Impact factor: 2.216

4.  Variations in the cerebrospinal fluid proteome following traumatic brain injury and subarachnoid hemorrhage.

Authors:  David E Connor; Ganta V Chaitanya; Prashant Chittiboina; Paul McCarthy; L Keith Scott; Lisa Schrott; Alireza Minagar; Anil Nanda; J Steven Alexander
Journal:  Pathophysiology       Date:  2017-05-13

Review 5.  Antifibrinolytic treatment in subarachnoid haemorrhage: present state.

Authors:  H Fodstad
Journal:  Acta Neurochir (Wien)       Date:  1982       Impact factor: 2.216

6.  Coagulation and fibrinolysis in blood and cerebrospinal fluid after aneurysmal subarachnoid haemorrhage: effect of tranexamic acid (AMCA).

Authors:  H Fodstad; I M Nilsson
Journal:  Acta Neurochir (Wien)       Date:  1981       Impact factor: 2.216

7.  Cerebral aneurysm: report of two cases and clinical update.

Authors:  L Morrow; A W Hilliard
Journal:  J Natl Med Assoc       Date:  1983-03       Impact factor: 1.798

8.  Determination of tranexamic acid (AMCA) and fibrin/fibrinogen degradation products in cerebrospinal fluid after aneurysmal subarachnoid haemorrhage.

Authors:  H Fodstad; A Pilbrant; M Schannong; S Strömberg
Journal:  Acta Neurochir (Wien)       Date:  1981       Impact factor: 2.216

9.  Comparative clinical trial of epsilon amino-caproic acid and tranexamic acid in the prevention of early recurrence of subarachnoid haemorrhage.

Authors:  U M Chowdhary; K Sayed
Journal:  J Neurol Neurosurg Psychiatry       Date:  1981-09       Impact factor: 10.154

10.  Prediction of cerebral vasospasm value of fibrinogen degradation products (FDP) in the cerebro-spinal fluid (CSF) for prediction of vasospasm following subarachnoid haemorrhage due to a ruptured aneurysm.

Authors:  M Guggiari; F Dagreou; M Rivierez; P Mottet; S Gallais; J Philippon; P Viars
Journal:  Acta Neurochir (Wien)       Date:  1984       Impact factor: 2.216

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.